Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Dendritic Cell Cancer Vaccine for High-grade Glioma (GBM-Vax)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Activartis Biotech
ClinicalTrials.gov Identifier:
NCT01213407
First received: May 28, 2010
Last updated: May 18, 2016
Last verified: May 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: November 2015
  Primary Completion Date: June 2015 (Final data collection date for primary outcome measure)